Posted on 290
Entrada Therapeutics, a privately-held biotechnology company dedicated to transforming the treatment of devastating diseases using intracellular biologics, today announced the appointment of Peter S. Kim, Ph.D., to its Board of Directors.
“Dr. Kim is a pioneering scientist with over 30 years of experience in both academia and the biopharmaceutical industry,” stated Dipal Doshi, President and CEO of Entrada Therapeutics. “He has been recognized with countless honors, awards and appointments throughout the course of his career and we are extraordinarily fortunate to welcome him to our Board of Directors. Dr. Kim’s scientific and drug development expertise and experience will contribute to Entrada’s success in developing groundbreaking therapies.”